Literature DB >> 15292671

Low platelet-poor plasma levels of serotonin in adult autistic patients.

Baruch Spivak1, Pavel Golubchik, Tamar Mozes, Yaffa Vered, Allon Nechmad, Abraham Weizman, Rael D Strous.   

Abstract

BACKGROUND: Hyperserotonemia has been reported in about a third of autistic patients. However, most studies have examined whole blood levels of serotonin (5-HT), the vast majority of which is found in platelets. The aim of this study was to determine 5-HT levels in platelet-poor plasma (PPP) in a group of adult patients with autism.
METHODS: Levels of PPP 5-HT were compared between 10 adult drug-free autistic patients and 12 healthy controls. The Ritvo-Freeman Real-Life Rating Scale and the Overt Aggression Scale (OAS) were administered to the autistic group as a measure of symptom severity.
RESULTS: Significantly lower PPP 5-HT levels were observed in the autistic group as compared to the controls (p = 0.03). In addition, PPP 5-HT levels were inversely correlated with OAS scores among subjects with autism (r = -0.64, p < 0.05).
CONCLUSION: PPP 5-HT ('free') levels appear to be low in autistic patients and may play a role in the pathophysiology and symptomatology of the disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292671     DOI: 10.1159/000079108

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  13 in total

1.  Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems.

Authors:  Elizabeth Hammock; Jeremy Veenstra-VanderWeele; Zhongyu Yan; Travis M Kerr; Marianna Morris; George M Anderson; C Sue Carter; Edwin H Cook; Suma Jacob
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-05-26       Impact factor: 8.829

2.  Dystrophic serotonin axons in postmortem brains from young autism patients.

Authors:  Efrain C Azmitia; Jorawer S Singh; Xiao P Hou; Jerzy Wegiel
Journal:  Anat Rec (Hoboken)       Date:  2011-09-08       Impact factor: 2.064

3.  Brief report: Platelet-poor plasma serotonin in autism.

Authors:  George M Anderson; Margaret E Hertzig; P A McBride
Journal:  J Autism Dev Disord       Date:  2012-07

4.  Hyperserotonemia in adults with autistic disorder.

Authors:  Dubravka Hranilovic; Zorana Bujas-Petkovic; Renata Vragovic; Tomislav Vuk; Karlo Hock; Branimir Jernej
Journal:  J Autism Dev Disord       Date:  2006-12-13

5.  Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice.

Authors:  Susanna Pietropaolo; Aurélie Guilleminot; Benoît Martin; Francesca R D'Amato; Wim E Crusio
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

Review 6.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

Review 7.  Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder.

Authors:  Valentina R Garbarino; T Lee Gilman; Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Res       Date:  2018-07-24       Impact factor: 7.658

8.  Evaluation of Pax6 mutant rat as a model for autism.

Authors:  Toshiko Umeda; Noriko Takashima; Ryoko Nakagawa; Motoko Maekawa; Shiro Ikegami; Takeo Yoshikawa; Kazuto Kobayashi; Kazuo Okanoya; Kaoru Inokuchi; Noriko Osumi
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240

Review 9.  Neuron membrane trafficking and protein kinases involved in autism and ADHD.

Authors:  Yasuko Kitagishi; Akari Minami; Atsuko Nakanishi; Yasunori Ogura; Satoru Matsuda
Journal:  Int J Mol Sci       Date:  2015-01-30       Impact factor: 5.923

10.  Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse.

Authors:  Jeremy Veenstra-Vanderweele; Tammy N Jessen; Brent J Thompson; Michelle Carter; Harish C Prasad; Jennifer A Steiner; James S Sutcliffe; Randy D Blakely
Journal:  J Neurodev Disord       Date:  2009-06       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.